Noble Biomaterials Raises $8M in Series B Equity Financing

Noble Biomaterials, Inc., a Scranton, PA-based provider of bacterial management solutions, has raised $8m in Series B equity financing.

The round was led by Northwater Capital’s Intellectual Property Fund with participation from existing investors TL Ventures and DuPont Capital Management.

The company intends to use the funding to expand growth initiatives and build its intellectual property management expertise.

Led by CEO CEO Jeff Keane, Noble develops, manufactures and markets advanced antimicrobial technologies designed to provide bacterial management, wound management and odor elimination solutions. Through its X-STATIC® system, the company delivers odor elimination solutions to sports apparel companies and bacterial management systems to global healthcare brands.
It has more than 200 global licensees for products in the medical, defense, industrial and consumer markets and has offices in Europe, Asia and South America.



Join the discussion